Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
July 27, 2020 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Zenosense, Inc.: Update on MIDS Medical Test Strip Development
March 20, 2019 07:30 ET
|
Zenosense, Inc.
VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and...
Direct Travel Expands Offerings to Clients with Zeno Travel Booking and Expense Solution in North America
March 19, 2019 08:00 ET
|
Direct Travel
Denver, March 19, 2019 (GLOBE NEWSWIRE) -- Travel management company Direct Travel, Inc., North America's fastest growing travel management company, today announced the expansion of its agreement...
Zenosense, Inc.: MIDS Medical JV to Receive Funding of Up to $1.2 Million
September 05, 2018 07:30 ET
|
Zenosense, Inc.
VALENCIA, SPAIN, Sept. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and...
Zenosense Trading on the OTCQB Venture Market
July 10, 2018 08:00 ET
|
Zenosense, Inc.
VALENCIA, SPAIN, July 10, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the...
Zenosense, Inc.: MIDS Shareholder Update
May 24, 2018 08:43 ET
|
Zenosense, Inc.
VALENCIA, SPAIN, May 24, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and...